Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1232-1238
Published online before print May 9, 2002, doi: 10.1161/01.ATV.0000021144.87870.C8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/7/1232    most recent
01.ATV.0000021144.87870.C8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, C.
Right arrow Articles by Anglés-Cano, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, C.
Right arrow Articles by Anglés-Cano, E.
Related Collections
Right arrow Risk Factors
Right arrow Fibrinolysis
Right arrow Fibrinogen/fibrin
Right arrow Thrombosis risk factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1232.)
© 2002 American Heart Association, Inc.


Thrombosis

Lp(a) Particles Mold Fibrin-Binding Properties of Apo(a) in Size-Dependent Manner

A Study With Different-Length Recombinant Apo(a), Native Lp(a), and Monoclonal Antibody

Chantal Kang*; Miguel Dominguez*; Stéphane Loyau; Toshiyuki Miyata; Vincent Durlach; Edouard Anglés-Cano

From INSERM U460 (C.K., M.D, S.L., E.A.-C.), Faculté de Médecine Xavier Bichat, Paris, France; the Laboratory of Thrombosis Research (T.M.), National Cardiovascular Center Research Institute, Osaka, Japan; and Service Endocrinologie-Diabetologie (V.D.), Centre Hospitalo-Universitaire de Reims, Reims, France.

Correspondence to Dr E. Anglés-Cano, INSERM U460, UFR de Médecine Xavier-Bichat, 16 rue Henri Huchard–BP 416, F-75870-Cedex 18, Paris, France.

Objective Small-sized apolipoprotein(a) [apo(a)] isoforms with high antifibrinolytic activity are frequently found in cardiovascular diseases, suggesting a role for apo(a) size in atherothrombosis. To test this hypothesis, we sought to characterize the lysine (fibrin)-binding function of isolated apo(a) of variable sizes.

Methods and Results Recombinant apo(a) [r-apo(a)] preparations consisting of 10 to 34 kringles and a monoclonal antibody that neutralizes the lysine-binding function were produced and used in parallel with lipoprotein(a) [Lp(a)] particles isolated from plasma in fibrin-binding studies. All r-apo(a) preparations displayed similar affinity and specificity for lysine residues on fibrin regardless of size (Kd 3.6±0.3 nmol/L) and inhibited the binding of plasminogen with a similar intensity (IC50 16.8±5.4 nmol/L). In contrast, native Lp(a) particles displayed fibrin affinities that were in inverse relationship with the apo(a) kringle number. Thus, a 15-kringle apo(a) separated from Lp(a) and a 34-kringle r-apo(a) displayed an affinity for fibrin that was higher than that in the corresponding particles (Kd 2.5 versus 10.5 nmol/L and Kd 3.8 versus 541 nmol/L, respectively). However, fibrin-binding specificity of the r-apo(a) preparations and the Lp(a) particles was efficiently neutralized (IC50 0.07 and 4 nmol/L) by a monoclonal antibody directed against the lysine-binding function of kringle IV-10.

Conclusions Our data indicate that fibrin binding is an intrinsic property of apo(a) modulated by the composite structure of the Lp(a) particle.


Key Words: lipoprotein(a) • apolipoprotein(a) • plasminogen • fibrin surfaces • fibrin affinity




This article has been cited by other articles:


Home page
CirculationHome page
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs
Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study
Circulation, March 29, 2005; 111(12): 1471 - 1479.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Tsurupa, B. Ho-Tin-Noe, E. Angles-Cano, and L. Medved
Identification and Characterization of Novel Lysine-independent Apolipoprotein(a)-binding Sites in Fibrin(ogen) {alpha}C-domains
J. Biol. Chem., September 26, 2003; 278(39): 37154 - 37159.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Hancock, M. B. Boffa, S. M. Marcovina, M. E. Nesheim, and M. L. Koschinsky
Inhibition of Plasminogen Activation by Lipoprotein(a): CRITICAL DOMAINS IN APOLIPOPROTEIN(a) AND MECHANISM OF INHIBITION ON FIBRIN AND DEGRADED FIBRIN SURFACES
J. Biol. Chem., June 20, 2003; 278(26): 23260 - 23269.
[Abstract] [Full Text] [PDF]